Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

We recently published a list of 13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds. In this article, we are ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $130 from $123 and keeps an Overweight rating on the ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...